title: Changes in serum runt-related transcription factor 2 levels after a 6-month treatment with recombinant human parathyroid hormone in patients with osteoporosis.
abstract: BACKGROUND
  The mechanisms regulating the anabolic response of the skeleton for recombinant human PTH (1- 34) [rhPTH (1-34)] administration has not been fully elucidated.
  
  
  OBJECTIVE
  The aim of this study was to evaluate the effect of rhPTH (1-34) on serum levels of runt-related transcription factor 2 (Runx2) in women with osteoporosis.
  
  
  METHODS
  Sixty post-menopausal women with osteoporosis (EO group) and 45 control subjects (NC group) were enrolled in this study. The EO group received daily injection of 20 μg rhPTH (1-34) plus oral 500 mg elemental calcium and 400 IU vitamin D3 for 6 months. Runx2 and Matrix metalloproteinase 13 (MMP-13) were measured with commercially available enzyme-linked immunosorbent assay kits. Bone mineral density (BMD) was also measured before and 6 months after rhPTH (1-34) treatment.
  
  
  RESULTS
  Serum total Ca2+, phosphate, and bone-specific alkaline phosphatase were significantly increased (p<0.05 or p<0.01), and the lumbar spine BMD (LS-BMD) was also increased by 4% in patients with osteoporosis after treatment with rhPTH (1-34) (p<0.05). On the contrary, serum Runx2 and MMP-13 were significantly decreased at post treatment (13.1% and 36.6%, respectively, p<0.05 and p<0.01). At baseline, serum Runx2 positively correlated with MMP-13 (r=0.74, p<0.01), the correction remained after adjusting for age and body mass index.
  
  
  CONCLUSIONS
  The daily injection of rhPTH (1-34) was able to stimulate bone formation. The therapy of 20 μg rhPTH (1- 34) for 6 months resulted in decrease of serum Runx2 and MMP-13. These changes might reflect the increase of active osteoblasts and the better bone homeostasis.
authors: Key Laboratory of Laboratory Medical Diagnostics, Ministry of Education and Department of Clinical Biochemistry, Chongqing Medical University College of Laboratory Medicine, Chongqing, China.
authors: W
authors: W
authors: Zhu
authors: M L
authors: ML
authors: Yang
authors: G Y
authors: GY
authors: Yang
authors: G
authors: G
authors: Boden
authors: L
authors: L
authors: Li
mesh_terms: D000469:Alkaline Phosphatase / Q000378:metabolism; D015415:Biomarkers / Q000097:blood; D015519:Bone Density; D016022:Case-Control Studies; D002762:Cholecalciferol / Q000008:administration & dosage; D050659:Core Binding Factor Alpha 1 Subunit / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D053509:Matrix Metalloproteinase 13 / Q000097:blood; D008875:Middle Aged; D010012:Osteogenesis / Q000502:physiology*; D015663:Osteoporosis, Postmenopausal / Q000097:blood* / Q000517:prevention & control*; D010281:Parathyroid Hormone / Q000008:administration & dosage*; D017698:Postmenopause; D011994:Recombinant Proteins / Q000378:metabolism; D013997:Time Factors
chemical_list: D015415:Biomarkers; D050659:Core Binding Factor Alpha 1 Subunit; C470125:PTH protein, human; D010281:Parathyroid Hormone; C493709:RUNX2 protein, human; D011994:Recombinant Proteins; D002762:Cholecalciferol; D000469:Alkaline Phosphatase; C507079:MMP13 protein, human; D053509:Matrix Metalloproteinase 13